De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DanCann Pharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
DanCann Pharma's earnings have been declining at an average annual rate of -61.8%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 39.2% per year.
Belangrijke informatie
-61.8%
Groei van de winst
11.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 30.5% |
| Inkomstengroei | 39.2% |
| Rendement op eigen vermogen | -931.5% |
| Nettomarge | -719.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe DanCann Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -59 | 8 | 0 |
| 31 Mar 24 | 7 | -61 | 8 | 0 |
| 31 Dec 23 | 7 | -62 | 9 | 0 |
| 30 Sep 23 | 7 | -15 | 9 | 0 |
| 30 Jun 23 | 8 | -15 | 9 | 0 |
| 31 Mar 23 | 7 | -16 | 9 | 0 |
| 31 Dec 22 | 7 | -16 | 9 | 0 |
| 30 Sep 22 | 7 | -15 | 8 | 0 |
| 30 Jun 22 | 4 | -15 | 8 | 0 |
| 31 Mar 22 | 4 | -13 | 8 | 0 |
| 31 Dec 21 | 2 | -12 | 7 | 0 |
| 30 Sep 21 | 1 | -9 | 5 | 0 |
| 31 Mar 21 | 0 | -6 | 4 | 0 |
| 31 Dec 20 | 0 | -4 | 3 | 0 |
| 30 Sep 20 | 0 | -2 | 2 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: DANCAN is currently unprofitable.
Groeiende winstmarge: DANCAN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DANCAN is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.
Versnelling van de groei: Unable to compare DANCAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: DANCAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.5%).
Rendement op eigen vermogen
Hoge ROE: DANCAN has a negative Return on Equity (-931.47%), as it is currently unprofitable.